HCC
Researchers Question Value of 30-Day Readmission Metric in HCC
Researchers at several centers across the country are raising doubts about rates of 30-day readmission after liver ...
FEBRUARY 22, 2022
BMS Withdraws Opdivo Indication for HCC Monotherapy
In consultation with the FDA, Bristol Myers Squibb (BMS) has voluntarily withdrawn from the U.S. market the ...
JULY 27, 2021
Nivolumab-Ipilimumab Combo Approved to Treat Previously Treated HCC
The FDA granted accelerated approval for the use of nivolumab plus ipilimumab to treat hepatocellular carcinoma in ...
MARCH 12, 2020
Report From HOPA 2019: Second-Line Treatment of Advanced HCC
Many clinicians continue to debate the best second-line agent for HCC from a multitude of options. At the 2019 ...
APRIL 4, 2019
FDA Grants Cabometyx New Indication for HCC
New treatment indicated for most common cause of liver cancer.
JANUARY 16, 2019
Keytruda Granted Accelerated Approval for Treatment of HCC
The FDA expanded the approved indications for pembrolizumab (Keytruda, Merck), granting the checkpoint inhibitor ...
NOVEMBER 16, 2018
Large Study Confirms DAAs Protect Against HCC When SVR Achieved
Patients with hepatitis C who are successfully treated with direct-acting antiviral agents experience a dramatic ...
MARCH 1, 2018
